为您找到相关结果约500个

你是不是要搜索 期刊IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups 点击跳转

IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastaticnonsquamous NSCLC (mNSCLC) across key subgroups

Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) plus chemotherapy (chemo) +/- bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC).

Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) plus chemotherapy(chemo) +/- bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.

IMpower151: Phase III Study of Atezolizumab plus Bevacizumab plus Chemotherapy in 1L Metastatic NonsquamousNSCLC

IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumabplus Bevacizumab

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLCPatient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

Atezolizumab and bevacizumab (atezo plus bev) ± radiotherapy (RT) vs docetaxel (doc) in checkpoint inhibitor(CPI)eexperienced metastatic NSCLC (mNSCLC): Results from the phase Ib/II MORPHEUS-lung study

Pembrolizumab plus Chemo versus Atezolizumab plus Chemo plus /-Bevacizumab for First-Line NonsquamousNSCLC: A Matching-Adjusted Indirect Comparison

Efficacy of atezolizumab (atezo) plus bevacizumab (bev) after disease progression with atezo monotherapy

Primary PFS and safety analyses of a randomized Phase III study of carboplatin plus paclitaxel plus /- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150)

Primary PFS and safety analyses of a randomized phase III study of carboplatin plus paclitaxel plus /- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)

Primary PFS and safety analyses of a randomized phase III study of carboplatin plus paclitaxel plus /- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150)

A phase Ib study of the safety and efficacy of atezolizumab (atezo) plus bevacizumab (bev) plus cobimetinib(cobi) in patients (pts) with metastatic colorectal cancer (mCRC)

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Bevacizumab Plus Atezolizumab in Pretreated Progressive and Metastatic NSCLC

为您找到相关结果约500个

共500条页码: 1/34页15条/页